4th Quarter - Report

KNIGHT CAPITOL CONSULTANTS for GENZYME CORPORATION

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Possible changes in the tax code that affect the pharmaceutical industry, including the R&D tax credit and the orphan drug tax credit.

Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Sen. Orrin G. Hatch

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Proposals that may affect the Medicare and Medicaid programs, including issues related to reimbursement under Medicare Part D, End Stage Renal Disease, and the Sustainable Growth Rate.

Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Sen. Orrin G. Hatch

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Implementation and possible change/repeal to provisions related to the Patient Protection and Affordable Care Act (PL 111-178) and the Reconciliation Act (PL 111-152), including implementation of biosimilars provisions and related issues such as data exclusivity and naming. Newborn Screening Saves Lives Reauthorization (PL 113-240).

Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Sen. Orrin G. Hatch

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Congressional oversight of the Food and Drug Administration's operations, including the approval pathways for biological and biosimilar products, and appropriations for FY 2015 (HR 83, Consolidated and Further Continuing Appropriations Act, 2015 (PL 113-235). General issues related to reimbursement for pharmaceuticals, including drug pricing, orphan drugs and reimbursement for pharmaceuticals under the 340B program.

Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Sen. Orrin G. Hatch

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 83 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.